Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer
Table 1
Patient characteristics for the four groups.
Group A ()
Group B ()
Group C ()
Group D ()
Total ()
Sex
Male
7
6
12
27
52
Female
4
8
9
17
38
Age, median (range)
62 (47–78)
61.5 (54–75)
63 (36–82)
64 (43–87)
63 (36–87)
Body weight, median (range)
59 (41–76)
60 (40–75)
58 (38–77)
59 (39–76)
59 (38–77)
PS
0
7
13
15
38
73
1
4
1
4
3
12
2
0
0
2
3
5
Primary tumor
Colon
4
5
10
21
40
Rectum
7
9
11
23
50
Metastasis
Liver
9
9
12
28
58
Lung
3
5
4
18
30
Lymph nodes
0
2
1
1
4
Other
2
4
7
8
21
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy. GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate; PS, performance status.
